

16 October 2018

Subject: Revision and resubmission of manuscript no: 41848

Dear Fang-Fang Ji, Science Editor, MSc.
Editorial Office, Baishideng Publishing Group Inc

Thank you for the opportunity to revise and resubmit our manuscript '*Probiotic Medilac-S® for the induction of clinical remission in a Chinese population with ulcerative colitis: A systematic review and meta-analysis*', by Ghania Sohail, Xiaoyu Xu, Mary C. Christman and Thomas A. Tompkins. We appreciate the insightful comments on the various components of the paper.

Please find below suggested revisions prompted by reviewers and our responses.

- 1. Suggestion by Reviewer 00503255:** The reviewer has requested the proper registration ® symbol be added after the name of our probiotic product Medilac-S.

Response: The reviewer is correct in that Medilac-S® is a brand name and as such, should be followed by the proper registration symbol. The symbol has now been added after all the entries of “Medilac-S®” in the manuscript.
- 2. Suggestion by Reviewer 00503255:** The reviewer suggested the term on page 14, line 21 "53 RCTs" should be changed to "53 Chinese RCTs".

Response: This was completed by authors and another similar statement on page 23, line 20 which simply stated “53 RCTs” was changed to “53 Chinese RCTs”.
- 3. Suggestion by Reviewer 00503255:** The reviewer requested the definition of “Mei-Changan” and “US-Changan” listed on page 9.

Response: “Mei-Changan” is one of the terms used in Chinese literature when describing the probiotic Medilac-S, as it is another trade name for Medilac-S, as registered by Hanmi pharmaceuticals. Please note, we modified the spelling of “Mei-Changan” to “MeiChangAn” as it is a more accurate representation of the word.

“US-Changan” is simply the English translation of the Chinese words 美常安 (Medilac-S®) and because this search term is equivalent to the original, we thought it best to remove this word from the list of search terms.

In addition, to more clearly represent the list of search terms presented on page 9, we added in the Chinese terms for the different aminosaliclates, including 美沙拉嗪 (mesalazine), 奥沙拉嗪 (olsalazine), and 柳氮磺胺吡啶 (sulfasalazine), to match the English search terms used. We apologize if we were not clear with our list of search terms upon initial submission and appreciate the comments from reviewers.

4. Suggestion by Reviewer 02549032: The reviewer suggested the statistical analysis presented in the manuscript be reviewed and controlled by a statistician.

Response: Dr. Mary Christman, a certified biostatistician and one of the manuscript's authors has thoroughly reviewed the manuscript and submitted a Biostatistician Review Letter prior to original submission, after which no data or statistics were modified.

Please note, Reviewer 02941672 did not prompt further modifications to the manuscript, stating,

“The author clarified the effectiveness of Medilac-S with SASP in inducing remission by meta-analysis. There is another meta-analysis, however the present study includes 53 trials which is more than double comparing previous one. This article is well summarized and no need for further revision.”

We thank Reviewer 02941672, 00503255 and 02549032 for their comments and we thank Baishideng Publishing Group Inc. for the continued interest in our research. We hope the revised manuscript will better suit the *World Journal of Clinical Cases*.

Sincerely,

Thomas A. Tompkins, Ph.D.

Research Director

Lallemand Health Solutions,

6100 avenue Royalmount

Montreal, QC

Canada H4P 2R2

tel: 514-944-3942

email: ttompkins@lallemand.com

